my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
07-05-2012: The Ludwig Institute for Cancer Research (LICR) announced the launch of a private biotechnology enterprise, iTeos Therapeutics SA, to develop a pre-clinical pipeline of immunomodulators to stimulate the immune system’s ability to attack cancer. Founded by LICR with the de Duve Institute at the Université catholique de Louvain (UCL), iTeos is led by a team experienced in tumor immunology, immunotherapy, drug discovery, business development and entrepreneurship. iTeos is the ninth new company formed based on innovative cancer research discoveries licensed from LICR.
iTeos’ initial goals are to reach a proof of concept in humans by completing a Phase I/IIa study for the first compound program and to submit an Investigational New Drug application for a second candidate in four years.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Pathway controlling cell growth revealed
A Melbourne-based research team has discovered a genetic defect that can halt cell growth and force cells into a death-evading survival state. The finding has revealed an important mechanism controlling the growth of rapidly-dividing cells that may ultimately lead to the development of new ... more
Nanosensors support skin cancer therapy
Malignant melanoma is the most aggressive type of skin cancer. In more than 50 percent of affected patients a particular mutation plays an important role. As the life span of the patients carrying the mutation can be significantly extended by novel drugs, it is very important to identify th ... more
iTeos Therapeutics launched to develop immunomodulators
The Ludwig Institute for Cancer Research (LICR) announced the launch of a private biotechnology enterprise, iTeos Therapeutics SA, to develop a pre-clinical pipeline of immunomodulators to stimulate the immune system’s ability to attack cancer. Founded by LICR with the de Duve Institute at ... more
Ludwig Institute for Cancer Research (LICR)
LICR is an international non-profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institu ... more
iTeos Therapeutics launched to develop immunomodulators
The Ludwig Institute for Cancer Research (LICR) announced the launch of a private biotechnology enterprise, iTeos Therapeutics SA, to develop a pre-clinical pipeline of immunomodulators to stimulate the immune system’s ability to attack cancer. Founded by LICR with the de Duve Institute at ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
